期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌组织KLF5表达临床意义分析 被引量：2

Analysis of clinical significance of KLF5 expression in breast cancer tissue
原文传递
导出
摘要 目的:检测锌指蛋白转录因子5(KLF5)在乳腺癌组织、癌旁组织及腺病组织中的表达,分析其在乳腺癌组织表达水平与临床病理特征的相关性。方法:免疫组化SP法检测100例乳腺癌组织、癌旁组织及20例乳腺腺病组织中KLF5的表达。结果:KLF5在乳腺癌细胞染色呈阳性,镜下可见大量棕褐色颗粒位于癌细胞胞质内,细胞核不被着色。癌旁组织和腺病组织可见棕黄色颗粒。100例乳腺癌组织中,KLF5的阳性表达率为74.0%(74/100),明显高于癌旁组织阳性表达率48.0%(48/100),差异有统计学意义,χ2=14.208,P=0.000;100例乳腺癌组织KLF5的阳性表达率,明显高于20例腺病组织阳性表达率35.0%(7/20),差异有统计学意义,χ2=11.556,P=0.001;乳腺癌旁组织阳性表达率与腺病组织比较,差异无统计学意义,χ2=1.135,P=0.287。KLF5在乳腺癌及癌旁组织中的表达情况与肿瘤大小差异有统计学意义,χ2=3.904,P=0.048,但与乳腺癌的病理类型、淋巴结转移、病理分级、ER及c-erbB-2等差异无统计学意义,P>0.05。结论:KLF5在乳腺癌组织中高表达,并且与肿瘤大小密切相关,但与乳腺癌的病理类型、淋巴结转移、病理分级及激素受体无关。KLF5有可能成为预测乳腺癌发生发展的重要肿瘤标志。 OBJECTIVE：By detecting the expression of KLF5 in breast cancer tissues,adjacent tissues and breast ad- enosis tissues,to analyze the relationship between the expression level of KLF5 in breast cancer and clinical characteris- tics. METHODS： By using immunohistochemistry methods the expressions of KLF5 in 100 cases of breast cancer tissues, 100 cases of adjacent tissues and 20 cases of breast adenosis tissues were detected. RESULTS：KLF5 staining was positive in breast cancer cells＇, there were large number of brown granules in the cytoplasm of cancer cells under microscope, and the nucleus were not being shaded. There were tan visible particles in adjacent to carcinoma and adenosis tissues. The positive expression rate of KLF5 in breast cancer tissues was 74.0 % （74/100） ,and it was dramatically higher than that in the adjacent tissues （48/100,48.0%, X2 = 14. 208, P= 0. 000）;The positive expressions of KLF5 in breast cancer tissues were dramatically higher than that in breast adenosis tissues （35.0 %, 7 / 20, ;（2 = 11.556, P = 0.001 ） ; There was no differ ence between the adjacent tissues and breast adenosis tissues（;（2 = 1. 135, P= 0. 287）. The tumor size had definite rela- tionships to the expressions of KLF5 in breast cancer and adjoining tissues （;（2 = 3. 904, P = 0. 048）. However, it had no significant difference with the pathological type of breast cancer, lymph node metastasis, pathological grading, or status of ER and c-erbB-2. CONCLUSIONS： KLF5 is highly expressed in breast cancer tissues,which is closely related to the tumor sizes,and had no relationship with the pathological type of breast cancer,lymph node metastasis, pathological grading and hormone receptors. KLF5 may possiblly becomes an important tumor marker to predict breast cancer development.
作者 吕昌新 丁宇 李良 王新美 韩红梅 李新兵 邱树升
机构地区 滨州医学院附属淄博市中心医院乳腺甲状腺外科 滨州医学院附属淄博市中心医院病理科
出处 《中华肿瘤防治杂志》 CAS 北大核心 2013年第11期850-852,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 乳腺肿瘤 病理学 锌指蛋白转录因子5 转录因子 免疫组织化学 breast neoplasms/pathology KLF5 transcription factors immunohistochemistry
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Yang HW,Xia T,Chen ZL,et al. Cloning,chromosomal localiza- tion and expression patterns of porcine Kriippel-like factors 4, -5,-7 and the early growth response factor 2 [J]. Biotechnol Lett,2007,29(1) :157-163.
  • 2Fromovitz FB,viola MV,Chao S,et al. ras P21 expression in the progression of breast cancer[J]. Hum pathol, 1987, 18 (12) : 1268-1275.
  • 3龚邵新,庄英帜,赵强,贺荣芳,丁慧,胡义燕,阳帅,曾庆彪.KLF4和KLF5蛋白在不同临床分期胃癌组织中的表达及意义[J].中国癌症杂志,2010,20(10):756-759. 被引量：12
  • 4Liu R,Zhou Z,Zhao D,et al. The induction of KLF5 transcrip tion factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation[J]. Mol En- docrinol,2011,25(7) :1137-1144.
  • 5Tong D,Czerwenka K,Heinze G,et al. Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast caneer[J]. Clin Cancer Res, 2006,12 (8) 2442-2448.
  • 6Chart SW, Lira CJ,Chen L, et al. The hippo pathway in biological control and cancer development[J]. J Cell Physiol, 2011,225 (1) :928-939.
  • 7Zhi X,Zhao D,Zhou Z,et al. YAP promotes breast cell prolifera- tion and survival partially through stabilizing the KLF5 tran seription faetor[J]. Am J Pathol,2012,180(6) :2452-2461.
  • 8徐静,刘丽丽,赵瑞霞,王琦,綦瑶,赵力.EZH2与乳腺癌及三阴性乳腺癌相关性的研究[J].中华肿瘤防治杂志,2010,17(24):2026-2029. 被引量：7
  • 9吴晖,欧阳取长,曾亮.年轻女性乳腺癌临床特点及其预后分析[J].中华肿瘤防治杂志,2010,17(14):1104-1106. 被引量：13

二级参考文献25

  • 1Gajdos C, Tartter P I, Bleiweiss I J, et al. Stage 0 to Ⅲ breast cancer in young women[J]. Jam Coll Surg,2000,190(5):523.
  • 2Lehman C D,Gat sonis C, Kuhl C K, et al . MRI evaluation of the eontralateral breast in women with recently diagnosed breast cancer[J]. N Engl J Med,2007,356(13):1295-1303.
  • 3Vaseoncelos A, Medeiro R, Veiga I, et al. Analysis of estrogenreceptor polymorphism in codon 325 by PCR2SSCP in breast cancer : association with lymph node metastasis[J]. Breast, 2002, 8(4) :226-229.
  • 4Klauber-DeMore N. Tumor biology of breast cancer in young women[J]. Breast Dis,2005-2006,23:9-15.
  • 5Aebi S. Special issues related to the adjuvant therapy in very young women[J]. Breast, 2005,14 ( 6 ) : 594-599.
  • 6Varambally S,Dhanasekaran S M,Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer[J]. Nature,2002,419(6907):624 -629.
  • 7Cardoso C, Mignon C, Hetet G, et al. The human EZH2 gene:genomic organization and revised mapping in 7q35 within the critical region for malignant myeloid disorders[J].Eur J Hum Genet, 2000, 8(3) :174-180.
  • 8Bachmann I M, Halvorsen O J, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggression tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast[J].J Clin Oneol, 2006, 24 (2):268-273.
  • 9Raaphorst F M, Meijer C J, Fieret E, et al. Poorly differentia ted breast cancer is associated with increased expression of the human polycomb group EZH2 gene[J].Neoplasia, 2003,5(6):481-488.
  • 10Ding L, Erdmann C, Chinnaiyan A M, et al. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues[J]. Cancer Res, 2006, 66 (8) : 4095-4099.

共引文献29

同被引文献25

  • 1Sun L,Zhao Y,Gu S, et al. Regulation of the HMOX1 gene bythe transcription factor AP-2S with unique DNA binding site[J],Mol Med Rep,2014,10(1) :423-428.
  • 2Berlato C, Chan KV, Price AM, et al. Alternative TFAP2A iso-forms have distinct activities in breast cancer[J], Breast CancerRes,2011,13(2) :R23.
  • 3Hung SW, Chiu CF, Chen TA, et al. Recombinant viral proteinVP1 suppresses HER-2 expression and migration/metastasis ofbreast cancer[J]. Breast Cancer Res Treat,2012,136 ( 1 ) : 89-105.
  • 4Powe DG, Akhtar G, Habashy HO. et al. Investigating AP-2 andYY1 protein expression as a cause of high HER2 gene transcrip-tion in breast cancers with discordant HER2 gene amplification[J].Breast Cancer Res, 2009,11 (6) .. R90.
  • 5. Breast Cancer Res, 2009 ,11(6) : R90.
  • 6Eletr ZM, Wilkinson KD. Regulation of proteolysis by human deu-biquitinating enzymes[J]. Biochim Biophys Acta, 2014, 1843(1):114-128.
  • 7Rathaus M,Lerrer B,Cohen HY. Deubikuitylation:a novel DUBenzymatic activity for the DNA repair protein, Ku70 [J]. CellCycle,2009,8(12):1843-1852.
  • 8Gong Y, Wang D,Dar JA,et al. Nuclear export signal of andro-gen receptor (NESAR) regulation of androgen receptor level inhuman prostate cell lines via ubiquitination and proteasome-de-pendent degradation [J]. Endocrinology, 2012,153 ( 12) : 5716-5725.
  • 9Wakahashi S,Sudo T,Oka N,et al. VAV1 represses E-cadherinexpression through the transactivation of Snail and Slug:a poten-tial mechanism for aberrant epithelial to mesenchymal transitionin human epithelial ovarian cancer[J]. Transl Res, 2013 , 162(3):181-190.
  • 10Powe DG, Akhtar G,Habashy HO,et al. Investigating AP-2 andYY1 protein expression as a cause of high HER2 gene transcrip-tion in breast cancers with discordant HER2 gene amplification[J]. Breast Cancer Res,2009,11(6) :R9.

引证文献2

二级引证文献3

中华肿瘤防治杂志
2013年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部